JULIAN BAKER
CIK 1087939 · last filed 2026-07-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.20B
Companies
38
Total Filings
403
Lifetime Open-Market Net
$3.10B
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| INCY | Director | 314,600 | $129.93 | $40.88M | $1.09B | 79 | 2026-07-02 |
| ONC | Director | 161,551 | $330.46 | $53.39M | $0 | 1 | 2026-06-15 |
| PRLD | Director | — | $4.64 | — | $0 | 3 | 2026-06-10 |
| TRDA | 10%+ Owner | 381,338 | $5.83 | $2.22M | $1.05M | 2 | 2025-11-24 |
| IGM Biosciences, Inc. (IGMS) Delisted | Director | 357,048 | $1.27 | $453.5K | $20.55M | 8 | 2025-07-02 |
| KYMR | Director | — | $106.16 | — | $0 | 1 | 2025-06-26 |
| KNSA | Director | 2,753,656 | $79.44 | $218.75M | $0 | 3 | 2025-06-05 |
| DNLI | Director | 3,415,958 | $24.05 | $82.15M | $0 | 1 | 2025-06-05 |
| BCYC | Director | 918,483 | $3.94 | $3.62M | $0 | 2 | 2025-01-06 |
| KALA | 10%+ Owner | 2,370 | $0.66 | $1.6K | $8.00M | 1 | 2024-12-31 |
| Talis Biomedical Corp (TLIS) Delisted | Director | — | $2.84 | — | $0 | 1 | 2022-06-13 |
| ACAD | Director | 3,609,489 | $26.01 | $93.88M | $0 | 8 | 2022-06-09 |
| KOD | Director | 15,604,214 | $40.29 | $628.69M | $568.05M | 4 | 2022-06-06 |
| TCRX | Director | — | $0.77 | — | $0 | 1 | 2022-06-03 |
| Neurogene Inc. (NLTX) Delisted | Director | — | $13.96 | — | $0 | 2 | 2022-05-16 |
| Spyre Therapeutics, Inc. (AGLE) Delisted | Director | — | $12.01 | — | $0 | 1 | 2021-02-25 |
| Atreca, Inc. (BCEL) Delisted | 10%+ Owner | 309,730 | $0.15 | $46.5K | $0 | 2 | 2020-07-20 |
| BeOne Medicines Ltd. (BGNE) Delisted | Director | 5,293,600 | $184.71 | $977.78M | $321.33M | 4 | 2020-06-19 |
| Seagen Inc. (SGEN) Delisted | Director | 46,041,889 | $228.74 | $10.53B | $1.10B | 32 | 2020-04-24 |
| ZYME | Director | — | $22.61 | — | $0 | 1 | 2020-03-16 |
| GENOMIC HEALTH INC (GHDX) Delisted | Director | 1,216,909 | — | — | -$101.91M | 69 | 2019-08-30 |
| Aceragen, Inc. (IDRA) Delisted | Director | 1,290 | $7.22 | $9.3K | -$13.97M | 22 | 2019-06-07 |
| BELLICUM PHARMACEUTICALS, INC (BLCM) Delisted | 10%+ Owner | 5,813 | $0.07 | $435 | -$28.88M | 1 | 2018-01-19 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | — | $58.70 | — | $0 | 1 | 2017-11-20 | |
| Invitae Corp (NVTA) Delisted | 10%+ Owner | — | $0.09 | — | $0 | 1 | 2017-08-02 |
| NTLA | 796,683 | $10.89 | $8.68M | $14.40M | 1 | 2016-05-11 | |
| Neurogene Inc. (AQXP) Delisted | 10%+ Owner | 826,628 | — | — | $27.87M | 3 | 2016-03-16 |
| XOMA | Director | 741,631 | $40.17 | $29.79M | $33.63M | 4 | 2014-12-30 |
| Ocera Therapeutics, Inc. (TZYM) Delisted | 10%+ Owner | 295,001 | — | — | $10.19M | 2 | 2012-03-14 |
| SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Director | 1,736,065 | — | — | $0 | 4 | 2012-01-09 |
| VIROPHARMA INC (VPHM) Delisted | 10%+ Owner | 303,264 | — | — | -$6.20M | 24 | 2011-12-16 |
| Ardea Biosciences, Inc./DE (RDEA) Delisted | Director | 126,709 | — | — | $52.46M | 11 | 2011-07-05 |
| AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | 10%+ Owner | 6,992 | — | — | $81.52M | 5 | 2011-03-31 |
| RPRX | 10%+ Owner | 44,970 | $59.97 | $2.70M | $1.22M | 4 | 2010-06-02 |
| NEUROGEN CORP (NRGN) Delisted | Director | 3,500,059 | — | — | $0 | 18 | 2009-12-17 |
| BCRX | 10%+ Owner | 4,090,786 | $9.74 | $39.84M | -$9.19M | 4 | 2009-06-01 |
| ALLOS THERAPEUTICS INC (ALTH) Delisted | 10%+ Owner | 2,022,293 | — | — | -$69.50M | 26 | 2009-02-06 |
| Aceragen, Inc. (IDP) Delisted | 10%+ Owner | 550,546 | — | — | -$9.23M | 11 | 2007-11-15 |
Recent Filings · Page 3 of 41
403 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-06-09 | ACAD | Grant (A) | +205,248 | $0 | EDGAR |
| 2022-06-06 | KOD | Buy (P) | +3,434,094 | $26.69M | EDGAR |
| 2022-06-03 | TCRX | Grant (A) | — | $0 | EDGAR |
| 2022-05-16 | Neurogene Inc. (NLTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-04-04 | INCY | Grant (A) | +5,280 | $0 | EDGAR |
| 2022-03-10 | INCY | Mixed | +2,574,480 | $173.94M | EDGAR |
| 2022-02-22 | INCY | Buy (P) | +3,154,824 | $214.41M | EDGAR |
| 2022-02-14 | INCY | Buy (P) | +9,590,244 | $641.71M | EDGAR |
| 2021-07-01 | KNSA | Grant (A) | — | $0 | EDGAR |
| 2021-06-24 | ACAD | Grant (A) | +153,384 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.